Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Chemokine Binding to Tenascin-C Influences Chemokine-Induced Immune Cell Migration.

Domaingo A. et al, (2023), Int j mol sci, 24

Investigating chemokine-matrix networks in breast cancer: tenascin-C sets the tone for CCL2

MIDWOOD KIM., (2023), Ijms

Matrix-Targeting Immunotherapy Controls Tumor Growth and Spread by Switching Macrophage Phenotype.

Deligne C. et al, (2020), Cancer immunol res, 8, 368 - 382

Structural Fuzziness of the RNA-Organizing Protein SERF Determines a Toxic Gain-of-interaction.

Meyer NH. et al, (2020), J mol biol, 432, 930 - 951

Heart-Type Fatty Acid-Binding Protein (H-FABP) and its Role as a Biomarker in Heart Failure: What Do We Know So Far?

Rezar R. et al, (2020), J clin med, 9

Designing an improved T-cell mobilising CXCL10 mutant through enhanced GAG binding affinity.

Gerlza T. et al, (2019), Protein eng des sel, 32, 367 - 373

[Eruptive epidermoid cysts after imiquimod treatment of recurrent basal cell carcinoma : A case report].

Woltsche N. et al, (2019), Hautarzt, 70, 363 - 366

More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis.

Gschwandtner M. et al, (2019), Front immunol, 10

Glycosaminoglycans are important mediators of neutrophilic inflammation in vivo.

Gschwandtner M. et al, (2017), Cytokine, 91, 65 - 73

Interfering with the CCL2-glycosaminoglycan axis as a potential approach to modulate neuroinflammation.

Gschwandtner M. et al, (2016), Neurosci lett, 626, 164 - 173

Preparation and Characterization of Glycosaminoglycan Chemokine Coreceptors.

Kitic N. et al, (2016), Methods enzymol, 570, 517 - 538

Glycosaminoglycan silencing by engineered CXCL12 variants.

Gschwandtner M. et al, (2015), Febs lett, 589, 2819 - 2824

A combinatorial approach to biophysically characterise chemokine-glycan binding affinities for drug development.

Gerlza T. et al, (2014), Molecules, 19, 10618 - 10634

Include forthcoming?